You may also like
ZymoGenetics Submits Citizen Petition to FDA Requesting Removal of Bovine Thrombin from Market in the Interest of Patient Safety
ZymoGenetics, Inc. (NASDAQ:ZGEN), announced today the submission of a Citizen Petition to the U.S. Food and Drug Administration (FDA) requesting that the FDA remove Thrombin-JMI® Thrombin, topical (bovine origin) from the market in the interest of patient safety. The Citizen Petition is prompted by recent reports of serious or fatal bleeding-related adverse events in surgical patients exposed to bovine (cattle-derived) thrombin.
3 min read
The Regenerative Effects of Platelet-Rich Plasma on Meniscal Cells In Vitro and Its In Vivo Application with Biodegradable Gelatin Hydrogel
The objective of the study was to test the hypothesis that platelet-rich plasma (PRP) enhances meniscal tissue regeneration in vitro and in vivo.
1 min read
Blood Loss after Cardiopulmonary Bypass, Standard vs Titrated Protamine: A Meta-Analysis
The aim of this meta-analysis was to determine whether standard or titrated dosing of protamine is more effective in facilitating haemostasis after cardiac surgery with cardiopulmonary bypass (CPB).
1 min read